These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 4565369)

  • 41. Our ancient heritage in blood clotting and some of its consequences.
    Laki K
    Ann N Y Acad Sci; 1972 Dec; 202():297-307. PubMed ID: 4508929
    [No Abstract]   [Full Text] [Related]  

  • 42. The influence of various plasma components on the lysis of dilute human blood clots.
    Gallimore MJ; Shaw JT
    Thromb Diath Haemorrh; 1969 Nov; 22(2):223-33. PubMed ID: 5380946
    [No Abstract]   [Full Text] [Related]  

  • 43. Some thoughts on the state in nature, biosynthetic origin, and function of factor XIII.
    Loewy AG
    Ann N Y Acad Sci; 1972 Dec; 202():41-58. PubMed ID: 4629558
    [No Abstract]   [Full Text] [Related]  

  • 44. Herparin and the stabilization of fibrin.
    Cuddigan BJ
    Nature; 1968 Feb; 217(5130):779-80. PubMed ID: 4966686
    [No Abstract]   [Full Text] [Related]  

  • 45. Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting.
    Greenberg CS; Miraglia CC; Rickles FR; Shuman MA
    J Clin Invest; 1985 May; 75(5):1463-70. PubMed ID: 2860124
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ClfA(221-550), a fibrinogen-binding segment of Staphylococcus aureus clumping factor A, disrupts fibrinogen function.
    Liu CZ; Shih MH; Tsai PJ
    Thromb Haemost; 2005 Aug; 94(2):286-94. PubMed ID: 16113817
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.
    Ammollo CT; Semeraro F; Incampo F; Semeraro N; Colucci M
    J Thromb Haemost; 2010 Apr; 8(4):790-8. PubMed ID: 20088944
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effect and mechanism of recombinant hirudin on fibrinolysis].
    Li M; Zhang RJ; Cao GX; Wan WX; Zhang LF; Jin J
    Yao Xue Xue Bao; 2006 Sep; 41(9):814-8. PubMed ID: 17111825
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fibrinoligase: the fibrin-stabilizing factor system of blood plasma.
    Lorand L
    Ann N Y Acad Sci; 1972 Dec; 202():6-30. PubMed ID: 4565370
    [No Abstract]   [Full Text] [Related]  

  • 50. Studies on soluble fibrin in plasma. 3. N-terminal analysis of a modified fraction I (Cohn) from plasmin- and thrombin-incubated plasma.
    Kierulf P
    Scand J Clin Lab Invest; 1973 Jan; 31(1):43-9. PubMed ID: 4687776
    [No Abstract]   [Full Text] [Related]  

  • 51. [Importance of the structure of the clot in thrombolysis].
    Soria C; Soria J; Mirshahi M; Desvignes P; Bonnet P; Caen JP
    Ann Biol Clin (Paris); 1987; 45(2):207-11. PubMed ID: 2441630
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acceleration of fibrin polymerization by calcium ions.
    Boyer MH; Shainoff JR; Ratnoff OD
    Blood; 1972 Mar; 39(3):382-7. PubMed ID: 5059648
    [No Abstract]   [Full Text] [Related]  

  • 53. Comparative studies on tissue transglutaminase and factor XIII.
    Chung SI
    Ann N Y Acad Sci; 1972 Dec; 202():240-55. PubMed ID: 4629552
    [No Abstract]   [Full Text] [Related]  

  • 54. Studies on the activation of human factor XIII.
    Sheltawy MJ; Miloszewski K; Losowsky MS
    Thromb Diath Haemorrh; 1972 Dec; 28(3):473-82. PubMed ID: 4675268
    [No Abstract]   [Full Text] [Related]  

  • 55. Clot lysis in a perfusion system.
    Bouvier CA; Gruendlinger J; Berthoud S
    Thromb Diath Haemorrh; 1966 Jan; 15(1):205-19. PubMed ID: 5919801
    [No Abstract]   [Full Text] [Related]  

  • 56. Equilibria in the fibrinogen--fibrin conversion. 8. Polymerization of acceptor-modified fibrin monomer.
    Endres GF; Scheraga HA
    Biochemistry; 1968 Dec; 7(12):4219-26. PubMed ID: 5750166
    [No Abstract]   [Full Text] [Related]  

  • 57. Increase in fibrinogen and fibrin-related antigen in human serum due to in vitro lysis of fibrin by thrombin.
    Merskey C; Johnson AJ; Lalezari P
    J Clin Invest; 1972 Apr; 51(4):903-11. PubMed ID: 5014617
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of Fibrinolysis by Coagulation Factor XIII.
    Rijken DC; Uitte de Willige S
    Biomed Res Int; 2017; 2017():1209676. PubMed ID: 28761875
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The conversion of fibrinogen to fibrin. XIII. Dissolution of fibrin and inhibition of clotting by various neutral salts.
    SHULMAN S; KATZ S; FERRY JD
    J Gen Physiol; 1953 Jul; 36(6):759-66. PubMed ID: 13069679
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Screening cleavage of Factor XIII V34X Activation Peptides by thrombin mutants: A strategy for controlling fibrin architecture.
    Jadhav MA; Goldsberry WN; Zink SE; Lamb KN; Simmons KE; Riposo CM; Anokhin BA; Maurer MC
    Biochim Biophys Acta Proteins Proteom; 2017 Oct; 1865(10):1246-1254. PubMed ID: 28687225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.